Abstract
Background: This study evaluated the biological properties of twelve 1,3-thiazolidin-4- ones by assessing antifungal and antibacterial activities.
Methods: All compounds were tested against three fungi and two bacteria. The lowest concentration that produced a ≥50% inhibition of the growth of yeast in comparison with positive control was identified as MIC50. Compound 1b showed the best antifungal result against Candida albicans with MIC50 100 μg/ml (52.38% of growth inhibition). In the antifungal Rhodotorula assay, two compounds showed good antifungal activity with MIC50 100 μg/ml (1f: 82.91% and 1i: 61.91%). For C. parapsilosis compound 1i has MIC50 200 μg/ml. Results and Conclusion: No antibacterial activity was found for Staphylococcus aureus and Escherichia coli at the highest concentration tested (400 μg/ml). The cytotoxicity study for three compounds was carried out against primary astrocyte cells and no toxic effect was found at 400 μM. This study discovered at least two potential compounds that will guide further chemical modification to search for better results.Keywords: 4-thiazolidinones, 1, 3-benzodioxol, candida albicans, candida parapsilosis, rhodotorula mucilaginosa, astrocytes.
Letters in Drug Design & Discovery
Title:Antimicrobial and Cytotoxicity Activities of 2-(aryl)-3-(benzo[d][1,3] dioxol-5-yl)thiazolidin-4-ones
Volume: 14 Issue: 9
Author(s): Silvana P. Souza, Hellen G. Masteloto, Daniel S. da Silva, Juliana H. Azambuja, Elizandra Braganhol, Juliana S. Ribeiro, Rafael G. Lund and Wilson Cunico*
Affiliation:
- CCQFA, Federal University of Pelotas, P.O. Box: 354, Pelotas,Brazil
Keywords: 4-thiazolidinones, 1, 3-benzodioxol, candida albicans, candida parapsilosis, rhodotorula mucilaginosa, astrocytes.
Abstract: Background: This study evaluated the biological properties of twelve 1,3-thiazolidin-4- ones by assessing antifungal and antibacterial activities.
Methods: All compounds were tested against three fungi and two bacteria. The lowest concentration that produced a ≥50% inhibition of the growth of yeast in comparison with positive control was identified as MIC50. Compound 1b showed the best antifungal result against Candida albicans with MIC50 100 μg/ml (52.38% of growth inhibition). In the antifungal Rhodotorula assay, two compounds showed good antifungal activity with MIC50 100 μg/ml (1f: 82.91% and 1i: 61.91%). For C. parapsilosis compound 1i has MIC50 200 μg/ml. Results and Conclusion: No antibacterial activity was found for Staphylococcus aureus and Escherichia coli at the highest concentration tested (400 μg/ml). The cytotoxicity study for three compounds was carried out against primary astrocyte cells and no toxic effect was found at 400 μM. This study discovered at least two potential compounds that will guide further chemical modification to search for better results.Export Options
About this article
Cite this article as:
Souza P. Silvana, Masteloto G. Hellen, da Silva S. Daniel, Azambuja H. Juliana, Braganhol Elizandra, Ribeiro S. Juliana, Lund G. Rafael and Cunico Wilson*, Antimicrobial and Cytotoxicity Activities of 2-(aryl)-3-(benzo[d][1,3] dioxol-5-yl)thiazolidin-4-ones, Letters in Drug Design & Discovery 2017; 14 (9) . https://dx.doi.org/10.2174/1570180814666170106143418
DOI https://dx.doi.org/10.2174/1570180814666170106143418 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals Autophagy : Moving Benchside Promises to Patient Bedsides
Current Cancer Drug Targets Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry Efficacy of Bacteria in Cancer Immunotherapy: Special Emphasis on the Potential of Mycobacterial Species
Clinical Cancer Drugs Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Feature Selection for Histopathological Image Classification using levy Flight Salp Swarm Optimizer
Recent Patents on Computer Science Structure Prediction of Neuroendocrine Convertase -2: A Potential Target in Various Cancers
Protein & Peptide Letters Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future
Current Immunology Reviews (Discontinued) Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting
Current Gene Therapy Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Small Molecule CXCR4 Chemokine Receptor Antagonists: Developing Drug Candidates
Current Medicinal Chemistry Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Cannabinoid Drugs and Enhancement of Endocannabinoid Responses: Strategies for a Wide Array of Disease States
Current Molecular Medicine